Lorbriqua Tablet (Lorlatinib): Targeted Treatment for ALK-Positive Lung Cancer

Lorbriqua Tablet contains Lorlatinib, a targeted cancer medicine known as a tyrosine kinase inhibitor used to treat advanced or metastatic non-small cell lung cancer (NSCLC) that is ALK-positive (has a specific genetic change). It works by blocking proteins that help cancer cells grow and spread, slowing tumor progression. This medicine is given when other ALK inhibitors have stopped working or as directed by an oncologist.
read more..